undamentalytics Newsletter
Sign in

Lipocine Inc. revenue

Lipocine Inc.'s revenue was $2.0m in fiscal 2025, down 82.3% on the year before. Since fiscal 2012 ($7.7m) it has grown at a compound -11.6% a year. Over the last twelve months it was $1.6m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8000000161−31122
Growth on the year before—−100.0%———−61.5%−100.0%—−96.9%−670.2%—−82.3%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $1.5M 75.9% ▼ 86.2%
Royalty $476,677 24.1% ▲ 59.9%

From Lipocine Inc.'s 10-K filed March 10, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lipocine Inc. $1.6m -62.7% 205.6%
Nutriband Inc. $1.6m -37.3% -10.8%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —
60 Degrees Pharmaceuticals, Inc. $1.1m 73.2% 74.9%
Eyepoint, Inc. $2.8m -94.6% -57.9%
Scienture Holdings, Inc. $821,315 540.6% -58.5%

Compare with peers

Head to head: LPCN vs NTRBLPCN vs SXTCLPCN vs SXTPLPCN vs SCNX

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Lipocine Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lipocine Inc.